The SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) infection was in 2020 responsible for new disease related chronic conditions which have been referred to as Post-COVID. To date it is still unknown how common this condition is and how it might effect the working of the Immune system. The aim of the study is therefore to monitor the onset of autoimmune diseases in a large observational study consisting of German health insurance data.
SARS-CoV-2 is a virus of the coronavirus family, which includes a large number of viruses that can cause a wide variety of diseases in humans. The SARS-CoV-2 virus causes acute symptoms associated with the infection and can cause chronic conditions known as Post-COVID. To understand how the virus might effect the working of the Immune system a large observational study of health insurance data from Germany was set up. The exposed patients were identified by a diagnosis indicating a confirmed laboratory test for COVID-19. The basic question concerns the burden of the Post-COVID condition. The study investigate which autoimmune diseases or groups of autoimmune diseases are more common in humans after the exposure to the virus compared to a matched unexposed cohort. Further will this be investigated in subgroups of the population.
Study Type
OBSERVATIONAL
Enrollment
641,407
The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
Center for Evidence-Based Healthcare, Technische Universität Dresden
Dresden, Saxony, Germany
Incidence of Addison's disease
Incidence of a diagnosis of Addison's disease recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Alopecia areata
Incidence of a diagnosis of Alopecia areata recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Autoimmune hemolytic anemia
Incidence of a diagnosis of Autoimmune hemolytic anemia recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Arteriitis temporalis
Incidence of a diagnosis of Arteriitis temporalis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Graves' disease
Incidence of a diagnosis of Graves' disease recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of ankylosing spondylitis
Incidence of a diagnosis of ankylosing spondylitis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Behcet's disease
Incidence of a diagnosis of Behcet's disease recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Churg-Strauss disease
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Incidence of a diagnosis of Churg-Strauss disease recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Morbus Crohn
Incidence of a diagnosis of Morbus Crohn recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Dermatomyositis
Incidence of a diagnosis of Dermatomyositis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Diabetes type I
Incidence of a diagnosis of Diabetes type I recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Dermatitis herpetiformis (Duhring's disease)
Incidence of a diagnosis of Dermatitis herpetiformis (Duhring's disease) recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of atopic dermatitis
Incidence of a diagnosis of atopic dermatitis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Guillain-Barré-syndrome
Incidence of a diagnosis of Guillain-Barré-syndrome recorded in inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Goodpasture syndrome
Incidence of a diagnosis of Goodpasture syndrome recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Hashimoto's thyroiditis
Incidence of a diagnosis of Hashimoto's thyroiditis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Autoimmune Hepatitis
Incidence of a diagnosis of Autoimmune Hepatitis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Juvenile rheumatoid arthritis
Incidence of a diagnosis of Juvenile rheumatoid arthritis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Kawasaki syndrome
Incidence of a diagnosis of Kawasaki syndrome recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Cutaneous lupus erythematosus
Incidence of a diagnosis of Cutaneous lupus erythematosus recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Cryoglobulinemia
Incidence of a diagnosis of Cryoglobulinemia recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Systemic lupus erythematosus
Incidence of a diagnosis of Systemic lupus erythematosus recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Morphea
Incidence of a diagnosis of Morphea recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Multiple sclerosis
Incidence of a diagnosis of Multiple sclerosis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Myasthenia gravis
Incidence of a diagnosis of Myasthenia gravis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Necrotizing vasculopathy
Incidence of a diagnosis of Necrotizing vasculopathy recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Bullous pemphigoid
Incidence of a diagnosis of Bullous pemphigoid recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Pemphigus vulgaris
Incidence of a diagnosis of Pemphigus vulgaris recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Polyarteritis nodosa
Incidence of a diagnosis of Polyarteritis nodosa recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Polymyalgia rheumatica
Incidence of a diagnosis of Polymyalgia rheumatica recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Polymyositis
Incidence of a diagnosis of Polymyositis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Psoriasis
Incidence of a diagnosis of Psoriasis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Idiopathic thrombocytopenic purpura
Incidence of a diagnosis of Idiopathic thrombocytopenic purpura recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of rheumatoid arthritis
Incidence of a diagnosis of rheumatoid arthritis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Sarcoidosis
Incidence of a diagnosis of Sarcoidosis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Sjögren's syndrome
Incidence of a diagnosis of Sjögren's syndrome recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Takayasu arteritis
Incidence of a diagnosis of Takayasu arteritis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Ulcerative colitis
Incidence of a diagnosis of Ulcerative colitis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Vitiligo
Incidence of a diagnosis of Vitiligo recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Wegener's disease
Incidence of a diagnosis of Wegener's disease recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of primary biliary cholangitis
Incidence of a diagnosis of primary biliary cholangitis recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of celiac disease
Incidence of a diagnosis of celiac disease recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2